Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InSphero to Distribute Dainippon Screen Imager for Rapid Profiling of 3D Microtissues

Published: Tuesday, April 08, 2014
Last Updated: Tuesday, April 08, 2014
Bookmark and Share
The Cell'iMager, to be marketed in the US and Europe, simplifies growth and morphological profiling of 3D microtissues.

InSphero AG and Dainippon Screen (Kyoto, Japan) announced today they have reached a
distribution agreement for InSphero to begin marketing Dainippon Screen's Cell'iMager in North
America and Europe. Dainippon Screen selected InSphero based on their in-depth know-how
pertaining to 3D microtissue biology and applications. The CelriMager is fully compatible with
InSphero's GravityTRAPTm 3D microtissue assay platform and other 3D-cell culture plates,
providing rapid, robust profiling of microtissue growth and morphology.

3D tumor microtissues or spheroids are increasingly used in drug discovery and development as
a more representative biological model for testing drug sensitivity and efficacy. Size and
morphology are important determinants to evaluate the biological behavior of 3D microtissues,
particularly in development of anti-cancer drugs, where monitoring cell growth is a particularly
critical endpoint. High-throughput, accurate assessment of 3D microtissue size and growth in
these applications is currently limited by sequential, time-consuming and often manual optical
measurements.

The innovative CelriMager's high-resolution scanning optics provide rapid direct measurement
of multiple endpoints, including microtissue diameter, area, pseudo-volume, and circularity at a
resolution of up to 9600 dpi. The system can analyze four 96- or 384-well plates in a single run,
in as little as one minute per plate, enabling fast and label-free visualization of even small size
differences. The scanner software is tailored for the analysis of 3D microtissues, allowing
adjustment of parameters such as focal plane, minimum and maximum object size, scan area,
and resolution for developing protocols specific to a given tissue type or assay.
The instrument is already broadly used in Japan and is now available in North America and
Europe through InSphero's experienced sales team.

InSphero CEO and co-founder Dr. Jan Lichtenberg sees the agreement as an exciting next step
toward making InSphero a total solution provider for the 3D cell culture marketplace. "Adding
the Cell3iMager to our portfolio gets us closer to offering our customers a complete set of
solutions for 3D cell based assays — from the assay-ready 3D cell model, to assay reagents and
instruments for endpoint analysis."

Mr. Kunihisa Hashimoto, General Manager of Dainippon Screen's Imaging and Solutions
Division, noted the agreement with InSphero is also a major step for Dainippon Screen.
"Combining InSphero's GravityTRAPTm plates and microtissues with the imaging technology of
our Cell'iMager is sure to streamline and simplify research using 3D tissue cultures. We are
excited to leverage InSphero's expertise in the 3D marketplace to help bring our innovative
imaging system to North America and Europe."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms
PerkinElmer named as exclusive distributor of InSphero 3D culture technology.
Thursday, August 06, 2015
InSphero AG Secures CHF 20 Million Series C Financing
3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Wednesday, July 15, 2015
InSphero AG Secures CHF 20 Million Series C Financing
Leading 3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.
Tuesday, July 14, 2015
InSphero Publishes 3D Tumor-Stroma Model for Non-Small Cell Lung Cancer
PLOS One article delivers promising co-culture method to mimic tumor microenvironment, demonstrating potential for biomarker and drug discovery.
Thursday, April 24, 2014
InSphero Announces Collaboration with NCATS
Study to characterize 460 NCATS anti-cancer agents in 3D tumor models generated using InSphero technology.
Friday, March 21, 2014
Scientific News
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!